Diabetes mellitus nursing: assessment, interventions, and patient education

Diabetes mellitus is the most common endocrine disorder worldwide, affecting over 38 million Americans and serving as the leading cause of chronic kidney disease, adult-onset blindness, and non-traumatic lower-extremity amputation in the United States. For nursing students, diabetes knowledge is essential on every clinical floor you will rotate through — medical-surgical, ICU, pediatrics, obstetrics, and community health. This reference covers the complete clinical picture: Type 1 versus Type 2 pathophysiology, ADA diagnostic criteria, nursing assessment priorities, insulin management, oral and injectable medications, hypoglycemia and hyperglycemic emergencies, diabetic complications, and patient education frameworks.

Use this page alongside the DKA pathophysiology reference for ketoacidosis specifics, the CKD/ESRD nursing guide for diabetic nephropathy, and the nursing lab values cheat sheet for glucose and HbA1c interpretation.

Type 1 versus Type 2 versus LADA: key differences

Understanding the distinctions between diabetes subtypes drives every assessment finding, medication choice, and teaching point. Type 1 and Type 2 are the two major classifications, but latent autoimmune diabetes in adults (LADA) is increasingly recognized and frequently misdiagnosed as Type 2.

Pathophysiology overview

Type 1 diabetes

Type 1 diabetes results from an autoimmune process that selectively destroys the insulin-producing beta cells of the pancreatic islets of Langerhans. The process involves T-cell mediated immunity, and circulating autoantibodies — glutamic acid decarboxylase (GAD65), islet tyrosine phosphatase 2 (IA-2), and zinc transporter 8 (ZnT8) — are detectable months to years before clinical onset. Symptoms appear when approximately 80–90% of beta cell mass has been destroyed.

Without insulin, glucose cannot enter most cells (skeletal muscle, adipose tissue) and accumulates in the blood. The body shifts to lipolysis for fuel, producing ketone bodies (acetoacetate, beta-hydroxybutyrate, acetone) that cause metabolic acidosis. This is the pathophysiology underlying diabetic ketoacidosis (DKA), which is often the initial presentation in undiagnosed Type 1 diabetes.

Type 2 diabetes

Type 2 diabetes develops through a dual defect: peripheral insulin resistance (primarily in skeletal muscle, liver, and adipose tissue) combined with progressive beta cell dysfunction. Early in the disease, the pancreas compensates for insulin resistance by producing more insulin (hyperinsulinemia). Over years, beta cells lose their ability to keep pace with demand, and blood glucose rises.

Key pathophysiological mechanisms include:

• Hepatic glucose overproduction — the liver fails to suppress gluconeogenesis despite elevated insulin levels
• Impaired glucose uptake — skeletal muscle takes up less glucose from the bloodstream
• Adipocyte dysfunction — increased free fatty acid release worsens insulin resistance (lipotoxicity)
• Incretin defect — reduced GLP-1 response leads to inadequate postprandial insulin secretion
• Alpha cell dysregulation — inappropriate glucagon secretion further raises blood glucose

Unlike Type 1, enough residual insulin production exists to prevent ketosis under normal conditions. However, severe physiologic stress (sepsis, MI, surgery) can precipitate DKA or, more commonly, hyperglycemic hyperosmolar state (HHS) in Type 2 patients.

Diagnosis and classification

The American Diabetes Association (ADA) 2025 Standards of Care establishes four diagnostic criteria — any one is sufficient for diagnosis when confirmed on a repeat test (unless the patient presents with unequivocal hyperglycemia and classic symptoms):

Important nursing considerations for HbA1c: Conditions that alter red blood cell turnover can produce falsely high or low HbA1c values. Hemoglobin variants (sickle cell trait, thalassemia), iron deficiency anemia, chronic kidney disease, and recent blood transfusion all affect accuracy. When results are discordant with glucose readings, a plasma glucose-based test should be used instead.

Gestational diabetes mellitus (GDM) is diagnosed by a 75-g OGTT at 24–28 weeks gestation using different thresholds (FPG ≥92, 1-h ≥180, 2-h ≥153 mg/dL — any one value met or exceeded). Women with GDM have a 50% lifetime risk of developing Type 2 diabetes.

Nursing assessment

Systematic assessment is the foundation of diabetes care. The classic presentation — the “3 Ps” (polyuria, polydipsia, polyphagia) — results directly from hyperglycemia: elevated blood glucose exceeds the renal threshold (~180 mg/dL), spilling glucose into the urine and pulling water with it (osmotic diuresis), causing dehydration and thirst. The body, unable to use glucose for fuel, triggers hunger despite elevated blood glucose.

Assessment priorities

• Vital signs — hypertension is common (affects 75% of adults with diabetes); orthostatic hypotension may indicate autonomic neuropathy
• Blood glucose monitoring — self-blood glucose monitoring (SBGM) timing, frequency, target ranges; document point-of-care values and trends
• HbA1c — reflects average blood glucose over the past 2–3 months; ADA target is <7% for most adults (individualized for elderly, pregnant, or critically ill patients)
• Skin assessment — acanthosis nigricans (velvety dark patches at skin folds, indicating insulin resistance), slow wound healing, candidal infections
• Foot assessment — inspect for ulcers, calluses, cracks, deformity; assess pedal pulses (dorsalis pedis, posterior tibial); test protective sensation with 10-g monofilament and 128-Hz tuning fork; check capillary refill
• Neurological — assess for peripheral neuropathy (numbness, tingling, burning in stocking-glove distribution), cranial nerve function, and autonomic signs (gastroparesis, bladder dysfunction, erectile dysfunction)
• Vision — ask about blurred vision, floaters; refer for annual dilated eye exam (diabetic retinopathy screening)
• Renal — annual urine albumin-to-creatinine ratio (UACR) and serum creatinine for GFR estimation; early detection of diabetic nephropathy is critical
• Psychosocial — screen for diabetes distress, depression, and disordered eating; diabetes burnout significantly affects adherence

Insulin management

Insulin is the cornerstone of Type 1 diabetes treatment and is frequently required in advanced Type 2 diabetes. Understanding onset, peak, and duration for each insulin type is one of the highest-yield NCLEX topics.

Basal-bolus versus sliding scale

Basal-bolus therapy provides a long-acting insulin (basal) for background glucose control plus a rapid-acting insulin (bolus) before each meal. This regimen mimics normal pancreatic insulin secretion and produces the best glycemic control.

Sliding-scale insulin uses only short or rapid-acting insulin dosed based on current blood glucose readings. The ADA and Endocrine Society recommend basal-bolus over sliding scale for hospitalized patients, because sliding scale is reactive — it treats hyperglycemia after it occurs without preventing it.

Nursing considerations for insulin administration

• Injection sites — abdomen (fastest absorption), outer thigh, upper arm, buttocks; rotate sites within the same region to prevent lipohypertrophy
• Storage — unopened vials: refrigerate (36–46°F / 2–8°C); in-use vials: room temperature for up to 28 days (check manufacturer guidelines); never freeze insulin
• Mixing insulins — when mixing NPH with regular in one syringe, draw clear (regular) before cloudy (NPH) to avoid contaminating the regular vial; never mix long-acting analogs with other insulins
• Sick day rules — never stop basal insulin during illness; blood glucose often rises due to stress hormones; check blood glucose every 4 hours; check urine ketones if BG >240 mg/dL; maintain hydration; contact the provider if vomiting prevents oral intake or ketones are moderate-to-large

Oral and injectable non-insulin medications

Pharmacologic therapy for Type 2 diabetes begins with lifestyle modifications and metformin. When monotherapy fails to achieve glycemic targets, additional agents are added based on comorbidities, side effect profiles, and patient preferences.

Metformin (biguanide) — first-line for Type 2 diabetes. Decreases hepatic glucose production and improves insulin sensitivity. Key nursing points: hold before and 48 hours after iodinated contrast procedures; contraindicated when eGFR <30 mL/min; monitor for lactic acidosis (rare but serious); GI side effects (nausea, diarrhea) improve with extended-release formulation.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) — block glucose reabsorption in the proximal tubule, causing glycosuria. Provide significant cardiovascular and renal benefits independent of glucose lowering, which has made them a preferred add-on for patients with heart failure or CKD. Watch for genital mycotic infections (candidiasis), urinary tract infections, volume depletion, and euglycemic DKA (a board-favorite NCLEX topic — DKA without extreme hyperglycemia).

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) — enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. Result in meaningful weight loss (5–15%). Key side effects: nausea (dose-dependent, improves over time), pancreatitis risk (teach patients to report severe abdominal pain radiating to the back), contraindicated with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome.

DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin) — increase incretin levels by blocking dipeptidyl peptidase-4 enzyme. Weight-neutral, well-tolerated, fewer hypoglycemia episodes. Monitor for joint pain and pancreatitis; dose-adjust in renal impairment (except linagliptin).

Sulfonylureas (glipizide, glyburide, glimepiride) — stimulate insulin secretion from pancreatic beta cells. Effective and inexpensive but carry the highest hypoglycemia risk among oral agents, especially in elderly patients and those with renal impairment. Advise patients to never skip meals while taking sulfonylureas.

Hypoglycemia management

Hypoglycemia (blood glucose <70 mg/dL) is the most common acute complication of insulin therapy and certain oral agents (sulfonylureas, meglitinides). It can be life-threatening if severe, causing seizures, loss of consciousness, and cardiac arrhythmias.

Signs and symptoms by severity

• Mild (adrenergic) — shakiness, tremor, diaphoresis, tachycardia, anxiety, hunger, pallor
• Moderate (neuroglycopenic) — confusion, difficulty concentrating, irritability, slurred speech, blurred vision, headache, dizziness
• Severe — seizures, loss of consciousness, inability to self-treat; requires assistance from another person

The 15-15 rule

1. Check blood glucose — confirm <70 mg/dL
2. Give 15 grams of fast-acting carbohydrate (4 oz juice, 3–4 glucose tablets, 1 tablespoon honey)
3. Wait 15 minutes and recheck
4. If still <70 mg/dL, repeat the 15 g of carbohydrate
5. Once BG ≥70 mg/dL, eat a snack with protein and complex carbohydrate to sustain levels

For severe hypoglycemia (unconscious patient):

• In hospital — administer IV dextrose 50% (D50W) 25 mL (12.5 g dextrose) — this is the first-line treatment
• Outside hospital — administer glucagon 1 mg IM/SC or intranasal glucagon (Baqsimi) 3 mg into one nostril; place the patient in the recovery position (never attempt oral glucose in an unconscious patient — aspiration risk)
• Whipple’s triad — confirms true hypoglycemia: (1) symptoms consistent with low glucose, (2) documented low plasma glucose, (3) symptom relief after glucose administration

Prevention

• Educate patients on matching insulin dose to carbohydrate intake
• Teach recognition of early adrenergic symptoms
• Advise carrying a fast-acting glucose source at all times
• Instruct on glucagon kit use for family members and caregivers
• Warn about hypoglycemia unawareness (autonomic neuropathy blunts adrenergic symptoms — common in long-standing diabetes)

Hyperglycemic hyperosmolar state (HHS)

HHS is a life-threatening hyperglycemic emergency seen predominantly in Type 2 diabetes, carrying a mortality rate of 10–20% — approximately ten times higher than DKA. It develops insidiously over days to weeks, which often delays recognition.

Why HHS lacks ketosis

In Type 2 diabetes, enough residual insulin is present to inhibit lipolysis and suppress ketone body formation. However, this insulin is insufficient to prevent hepatic glucose overproduction and promote cellular glucose uptake. The result is extreme hyperglycemia without the ketoacidosis seen in DKA.

Nursing management of HHS

1. Aggressive fluid resuscitation — isotonic saline (0.9% NaCl) at 15–20 mL/kg/h for the first hour; switch to 0.45% NaCl once serum sodium is corrected; average fluid deficit is 8–12 liters
2. Insulin therapy — IV regular insulin infusion; start only after initial fluid bolus; target glucose reduction of 50–75 mg/dL per hour (avoid rapid drops to prevent cerebral edema)
3. Electrolyte monitoring — check potassium, sodium, phosphorus every 2–4 hours; replace potassium when serum K+ drops below 5.0 mEq/L (insulin drives potassium intracellularly)
4. Neurological monitoring — assess mental status hourly; altered consciousness correlates with osmolality
5. Identify and treat the trigger — infection accounts for 50–60% of HHS cases; also consider medication non-adherence, new diabetes diagnosis, MI, and stroke

For detailed DKA management, see the DKA pathophysiology reference.

Diabetic complications

Chronic hyperglycemia damages blood vessels through several mechanisms: glycation of proteins (advanced glycation end products), oxidative stress, activation of protein kinase C, and polyol pathway accumulation. These processes produce two categories of vascular damage.

Macrovascular complications

• Coronary artery disease (CAD) — diabetes increases CAD risk 2–4 fold; it is the leading cause of death in patients with Type 2 diabetes. Aggressive blood pressure and lipid management are essential. See the MI/ACS nursing reference for acute coronary syndrome management.
• Peripheral arterial disease (PAD) — reduced perfusion to the lower extremities impairs wound healing and increases amputation risk. Nursing assessment: palpate dorsalis pedis and posterior tibial pulses, assess capillary refill, check ankle-brachial index (ABI <0.9 is abnormal).
• Cerebrovascular disease — diabetes doubles stroke risk. For stroke recognition and management, see the stroke nursing reference.

Microvascular complications

• Diabetic nephropathy — the leading cause of ESRD in the United States. Hyperglycemia damages the glomerular capillaries, progressing from microalbuminuria (UACR 30–300 mg/g) to macroalbuminuria to progressive GFR decline. ACE inhibitors or ARBs are first-line for renoprotection. SGLT2 inhibitors provide additional nephroprotective benefit. For staging, dialysis, and nursing care, see the CKD/ESRD nursing guide.
• Diabetic retinopathy — the leading cause of blindness in working-age adults. Progresses from non-proliferative (microaneurysms, dot hemorrhages) to proliferative (neovascularization, vitreous hemorrhage). Annual dilated eye exams are mandatory. Tight glycemic and blood pressure control slows progression.
• Diabetic neuropathy — affects up to 50% of patients with diabetes. Peripheral neuropathy presents as numbness, tingling, and burning in a stocking-glove distribution. Autonomic neuropathy can affect the GI tract (gastroparesis), cardiovascular system (resting tachycardia, orthostatic hypotension), and genitourinary system (neurogenic bladder, erectile dysfunction). Nursing priority: daily foot inspection and protective footwear to prevent undetected injury.

Diabetic foot complications

Diabetic foot disease results from the convergence of neuropathy (loss of protective sensation), PAD (impaired healing), and immune dysfunction (increased infection risk). Nursing interventions:

• Perform comprehensive foot exams at every visit
• Test with 10-g monofilament at 4 plantar sites per foot
• Teach patients to inspect feet daily, wear well-fitting shoes, avoid walking barefoot, trim toenails straight across, and report any wound immediately
• Refer to podiatry for calluses, deformities, or active wounds

Patient education: the AADE7 framework

The Association of Diabetes Care and Education Specialists (ADCES, formerly AADE) identifies seven self-care behaviors that form the foundation of diabetes education. Use this framework to organize patient teaching:

1. Healthy eating — carbohydrate counting or the plate method (half vegetables, quarter protein, quarter carbohydrate); consistent meal timing; limit processed foods and sugary beverages
2. Being active — ADA recommends 150 minutes of moderate-intensity aerobic activity per week plus 2–3 sessions of resistance training; exercise lowers blood glucose by increasing insulin sensitivity
3. Monitoring — teach SBGM technique, frequency, target ranges, and how to use results for decision-making; discuss continuous glucose monitor (CGM) options when appropriate
4. Taking medications — insulin injection technique (45–90° angle, avoid intramuscular injection in thin patients), rotation of sites, proper storage, timing relative to meals; oral medication timing and food interactions
5. Problem solving — sick day management (never stop basal insulin, check BG every 4 hours, check ketones if BG >240 mg/dL, maintain hydration, contact provider if unable to keep fluids down); what to do when blood glucose is too high or too low
6. Reducing risks — annual eye exam, annual foot exam, annual UACR and GFR, lipid panel, blood pressure monitoring, influenza and pneumococcal vaccines, smoking cessation, dental care
7. Healthy coping — address diabetes distress, connect with support groups, recognize burnout, screen for depression (PHQ-2/PHQ-9)

Sick day rules (teach every patient)

• Continue basal insulin even if unable to eat
• Check blood glucose every 4 hours
• Check urine or blood ketones if BG >240 mg/dL
• Drink 8 oz of calorie-free fluid every hour
• Contact the provider for: persistent vomiting, moderate-to-large ketones, BG >300 mg/dL despite extra insulin, signs of dehydration, or illness lasting >24 hours

HbA1c targets and estimated average glucose

The formula for converting HbA1c to estimated average glucose (eAG): eAG (mg/dL) = 28.7 × HbA1c − 46.7 (ADAG study). ADA recommends HbA1c <7% for most non-pregnant adults, with individualized targets: tighter control (<6.5%) for younger patients without significant hypoglycemia, and relaxed targets (<8%) for elderly patients with limited life expectancy or multiple comorbidities.

NCLEX tips for diabetes nursing

• Hypoglycemia is more immediately dangerous than hyperglycemia — when a question asks about priority nursing actions, treat low blood glucose before addressing high blood glucose.
• Check potassium before starting insulin — insulin drives K+ into cells. If K+ is <3.5 mEq/L, hold insulin and replace potassium first. This applies to DKA, HHS, and sliding-scale insulin.
• Regular insulin is the only insulin given IV — all other insulins are subcutaneous only. This is a frequently tested point.
• NPH is the only cloudy insulin — all analog insulins (rapid, long, ultra-long) are clear. If a question describes a cloudy insulin, it is NPH. Roll gently to mix — never shake.
• Draw clear before cloudy — when mixing regular and NPH in one syringe, always draw regular (clear) first to prevent NPH from contaminating the regular vial.
• Dawn phenomenon versus Somogyi effect — dawn phenomenon is early morning hyperglycemia caused by growth hormone and cortisol surges (treat by adjusting evening basal insulin). Somogyi effect is rebound hyperglycemia following nocturnal hypoglycemia (treat by reducing evening insulin or adding a bedtime snack). Check a 3 AM blood glucose to differentiate.
• Rotate injection sites within the same anatomical region — rotating between different regions (e.g., abdomen to thigh) causes unpredictable absorption rates. Rotate within the abdomen, spacing injections at least 1 inch apart.
• Foot care is a priority nursing intervention — patients with diabetes should inspect feet daily, never walk barefoot, avoid heating pads on feet, and report any break in skin integrity immediately.
• HHS has higher mortality than DKA — HHS mortality is 10–20% versus 0.2–2.5% for DKA, because HHS patients are typically older with more comorbidities and present with severe dehydration.
• Metformin does not cause hypoglycemia when used alone — it does not stimulate insulin secretion. Sulfonylureas and insulin carry the highest hypoglycemia risk.

Related references

Build a complete endocrine and metabolic nursing library with these companion pages:

• DKA pathophysiology: assessment and management — the acute ketoacidosis emergency reference
• CKD and ESRD nursing guide — covers diabetic nephropathy, KDIGO staging, and dialysis
• Nursing lab values cheat sheet — glucose, HbA1c, BMP, and renal panel interpretation
• Electrolyte imbalances nursing reference — potassium and sodium disorders relevant to DKA and HHS
• Heart failure pathophysiology — diabetic cardiomyopathy and the cardiovascular-metabolic connection
• MI/ACS nursing reference — coronary artery disease management in patients with diabetes
• Drug classifications nursing guide — broader medication reference including antidiabetic agents
• Stroke nursing reference — cerebrovascular disease in diabetes

Clinical references: ADA Standards of Care in Diabetes — 2025, StatPearls Type 2 Diabetes Mellitus (NCBI NBK568737), StatPearls Hyperosmolar Hyperglycemic Syndrome (NCBI NBK482142), CDC National Diabetes Statistics Report 2024, ADAG Study (Nathan et al., Diabetes Care 2008).